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Objectives We aimed to study the prevalence of Fabry disease (FD) in patients with hypertrophic cardiomyopathy (HCM).
Background There are limited and controversial data about the prevalence of FD in patients with HCM.
Methods We screened the plasma -galactosidase A activity from 508 unrelated patients with HCM (328 men, 180
women, ages 58  16 years). Patients with low activity (0% to 30% of the normal control in men, and 0% to
50% in women) underwent genetic study of the GLA gene.
Results We found low plasma activity in 15 patients (3%). Three men had GLA mutations (0.9%): S238N (novel) in
2 and E358del (described) in 1. Two women had described mutations (1.1%): L89P and A143T. Three unre-
lated men had the D313Y variant previously associated with enzyme pseudo-deficiency. Two women had
polymorphisms that did not segregate with the disease in their families. Five women (activitiy 39% to 47%)
had no sequence variants. The familial studies allowed the diagnosis of 14 carriers: 6 women without
Fabry manifestations, 3 women with cardiomyopathy, 2 men with renal and cardiac disease, 1 man with
microhematuria, 1 woman with first-degree atrioventricular block, and a 32-year-old woman with only renal
disease.
Conclusions By means of a screening based on genotyping of patients with low plasma enzymatic activity, the prevalence
of FD in our population of HCM is 1% (0.9% in men and 1.1% in women). This diagnosis is relevant, because it
allows the identification of disease carriers that might benefit from enzyme replacement therapy. (J Am Coll
Cardiol 2007;50:2399–403) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.062d
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aore than 400 different mutations in genes encoding
arcomeric proteins have been associated with hypertrophic
ardiomyopathy (HCM) (1,2); however, even after a sys-
ematic screening, mutations in these genes are not found in
0% to 40% of the patients (1). Recently, several studies
ave identified Fabry disease (FD) as a relatively frequent
ause of idiopathic left ventricular hypertrophy (3–5). Fabry
rom the *Complejo Hospitalario Universitario Juan Canalejo, A Coruña, Spain;
Hospital Virgen de la Arrixaca, Murcia, Spain; ‡Hospital General de Alicante,
licante, Spain; §Hospital Clinic, Barcelona, Spain; Fundacio´n Jiménez Dı´az,
uto´noma University, Madrid, Spain; and ¶Red Tema´tica de Investigacio´n Cardio-
ascular (RECAVA)-Instituto Salud Carlos III, Madrid, Spain. This study was
upported by the Red Tema´tica de Investigacio´n Cardiovascular (RECAVA) of the
nstituto de Salud Carlos III, Madrid, Spain. Dr. Monserrat is funded by a research
rant from the Sanofi-Aventis Foundation.w
Manuscript received February 12, 2007; revised manuscript received May 25, 2007,
ccepted June 5, 2007.isease is an X-linked lysosomal -galactosidase A defi-
iency that causes multisystemic problems, including renal,
eurological, ocular, skin, and cardiac manifestations. There
s a classical form of the disease characterized by early
anifestation of the multisystemic disorder. But there are
lso atypical forms with late-onset isolated renal or cardiac
See page 2404
anifestations, usually in men with some residual plasma
nzymatic activity or in female carriers (3–6). Cardiac involve-
ent in FD is related to the accumulation of glycosphingolip-
ds in the myocardium, valvular, and conduction tissues,
eading to increase in wall thickness, mitral valve thickening,
nd conduction system disease (7). Although patients with
pparently isolated cardiac involvement might be diagnosed
ith HCM, there are very few studies of the prevalence of FD
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with controversial results (3–6).
The objective of this study is
to evaluate the prevalence of FD
in a wide nonselected population
of patients previously diagnosed
with HCM.
ethods
e studied 508 consecutive unrelated patients from 3
egional centers (Coruña, in northern Spain; Murcia and
licante, in southern Spain) with HCM diagnosed accord-
ng to the criteria of the World Health Organization and of
he European Society of Cardiology Working Group on
yocardial and Pericardial Diseases (1,8,9). For each pa-
ient, a complete pedigree was drawn, and all of the
rst-degree relatives were invited to be screened. All pa-
ients gave written informed consent for the clinical, mo-
linical Characteristics and Suddeneath Risk F o of the Index Patients
Table 1 Clinical Characteristics and SuddenDeath Risk Factors of the Index Patients
Coruña Murcia Alicante Total
Maximum left ventricular wall
thickness (mm)
20 6 20 4 21 5 20 5
Subaortic obstruction (%) 25 32 56 36
Nonsustained ventricular
tachycardia (%)
25 30 26 26
Previous syncope (%) 13 37 21 17
Abnormal exercise blood
pressure response (%)
34 23 46 37
Maximum left ventricular wall
thickness 30 mm (%)
7 3 8 6
Family history of premature
sudden death (%)
10 18 31 19
enotype and Phenotype in the Index Patients With Low Enzymatic
Table 3 Genotype and Phenotype in the Index Patients With Lo
1 2 3 4
Center C C M A
Age (yrs) 70 74 50 48
Gender F F M M
Enzymatic activity
(% of control)
19 25 12 20
GLA mutation L89P A143T E358del S238N
GLA polymorphism    
Maximum left ventricular
wall thickness (mm)
14 21 20 17
Renal disease    
Conduction defect    
Cardiac disease in the family    
Renal disease in the family    
Abbreviations
and Acronyms
FD  Fabry disease
HCM  hypertrophic
cardiomyopathy 15.
A  Alicante; C  Coruña; M  Murcia.ecular biology, and genetic studies, and the institutional
thics committees approved the protocol.
Plasma and genomic deoxyribonucleic acid (DNA) ex-
racted from lymphocytes were stored at 80°C for subse-
uent analysis. The -galactosidase A was assayed fluoro-
etrically as described by Beutler and Kuhl (10) with the
odifications of Mayes et al. (11). The specific activity was
xpressed as percentage of the mean values of normal
ontrol subjects matched by age and gender. Patients with
ow activity (0% to 30% of the normal control subjects in
en and 0% to 50% in women) were submitted to genetic
tudy of the GLA gene (direct sequencing of exons 1 to 7).
he DNA mutations are described according to GLA com-
lementary DNA sequence (12), with the A of the ATG
nitiation codon being 1. The diagnosis of FD was done in
hose patients with low enzymatic activity who also potentially
ad disease-causing mutations in the GLA gene (6).
ummary of the Enzymatic andenetic Screening of the Index Patients
Table 2 Summary of the Enzymatic andGenetic Screening of the Index Patients
Coruña Murcia Alicante Total
Patients (n) 200 148 160 508
Male gender (%) 64 76 55 65
Age (yrs) 58 15 55 16 59 18 58 16
Age 40 yrs (%) 87 83 82 84
Plasma enzymatic activity
(% of control)
83 26 112 47 104 29 99 37
Men with enzymatic activity
30, n (%)
1 (0.7) 3 (2.4) 2 (2.3) 6 (1.8)
Women with enzymatic
activity 50, n (%)
9 (12.5) 0 0 9 (5)
Patients with low enzymatic
activity, n (%)
10 (5) 3 (2) 2 (1.3) 15 (3)
Patients with GLA
polymorphisms, n (%)
3 (1.5) 2 (1.4) 0 5 (1)
Patients with GLA
mutations, n (%)
2 (1) 1 (0.7) 2 (1.3) 5 (1)
ivity
zymatic Activity
Patient #
6 7 8 9 10 11 12 13 14 15
M M C C C C C C C C
81 54 55 24 60 76 59 50 74 58
M M M F F F F F F F
22 22 23 42 44 39 43 44 46 47
N          
         
20 25 15 42 21 21 15 17 25 33
         
         
         
         Act
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e studied 328 men and 180 women. Tables 1 and 2
ummarize their clinical characteristics and the results of the
nzymatic screening. We found low plasma activity in 15
atients (3%): 6 men (1.8%) and 9 women (5%). The
linical characteristics and the results of the genetic study of
Figure 1 Pedigrees of the Families With Fabry Disease
Circles are women and squares are men. Filled symbols are affected patients (all
Dotted symbols are patients with mutation without apparent clinical manifestation
confirmed phenotype but possibly affected. Numbers are ages. Index patients are
electrocardiogram; echo  echocardiogram; HCM  hypertrophic cardiomyopathy;
hypertrophy; TX  transplant.hese 15 patients are shown in Table 3. We found 3 Treviously described mutations (L89P, A143T, and
358del) and 1 novel mutation: S238N (in 2 patients).
hree men had the D313Y variant that has been previously
ssociated with enzymatic pseudo-deficiency. Two women
ad polymorphisms that did not segregate with the disease
n their families. In 5 women with low plasma enzymatic
ctivity, no sequence variant was found in the GLA gene.
utation). Symbols with an “N” indicate unaffected relatives without mutation.
hed symbols are deceased patients. Question marks indicate unknown or not
ted by the thick arrows. AF  atrial fibrillation; AV  atrioventricular; ECG 
implantable cardioverter-defibrillator; LV  left ventricular; LVH  left ventricularwith m
s. Das
indica
ICD he prevalence of FD was 1% in the whole population
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Fabry Disease in Hypertrophic Cardiomyopathy December 18/25, 2007:2399–4030.9% in men and 1.1% in women): 1.0% in Coruña, 0.7%
n Murcia, and 1.3% in Alicante. Figure 1 summarizes the
esults of the familial studies.
iscussion
ur study shows a 1% prevalence of FD in unselected
atients with HCM. Previous studies with lower number of
atients had found higher prevalences (3–5). Nakao et al.
3) identified 7 patients with FD among a cohort of 230
en (3%) with left ventricular hypertrophy. Sachdev et al.
4) found 6 patients with FD among 153 men with HCM
4%), with a prevalence of 6% in men diagnosed at older
han 40 years of age. Of note, 3 of the 6 patients carried the
ame mutation, suggesting a potential founder effect. In
ontrast, in 100 HCM patients that underwent septal
blation, Ommen et al. (13) could not find any FD. The
eason for this negative finding could be that the hypertro-
hy secondary to FD is usually concentric and not associated
ith the generation of dynamic subaortic obstruction (3–
,7,13). Chimenti et al. (5) identified 4 patients with FD in
group of 34 women (12%) with HCM who underwent
ndomyocardial biopsy. We can speculate about a poten-
ial selection bias in this study, because endomyocardial
iopsy is not a routine test in patients with HCM, but it
s usually done in patients with restrictive physiology or
ith a clinical suspicion of a myocardial infiltrative
isease. We think that the prevalence of FD found in our
ohort is probably more representative of the true prev-
lence of the disease in HCM. The prevalence of HCM
n the adult general population is 1 in 500 (1). So, with
prevalence of FD of 1 in 100 in patients with HCM, the
revalence of FD with left ventricular hypertrophy would
e 1 in 50,000 in the general population (1:500  1:100),
hich is near to the current estimation of FD prevalence
6,14). However, a recent study suggests that milder
orms of FD with late or incomplete penetrance and
robably without overt cardiac manifestations might be
ore frequent (15).
We have found a similar prevalence of FD in men and
omen with a screening based in the measurement of the
-galactosidase A enzymatic activity in plasma. This
ethod is useful for the diagnosis of male patients, who
sually present with very low enzymatic activity (6); but in
emale carriers, plasma enzymatic activity might be within
he normal range, and the screening could have a significant
umber of false negative results (5,6). To minimize this
ossibility, we have sequenced the GLA gene in 7 women
ith a borderline activity (30% to 50% of the control) that
epresents 4% of our female cohort, and we found several
olymorphisms but no pathogenic mutation. With these
esults, we consider that a screening strategy based on the
lasma enzymatic activity measurement is cost-effective
ot only in men but also in women with HCM. Sequenc-ng of the GLA gene would be limited to the men andomen with low activity and to women that even with a
ormal or borderline activity had other clinical or familial
haracteristics that could suggest the diagnosis of FD
renal disease, early cerebrovascular disease, angiokera-
oma, corneal opacities, heat intolerance, hypoacusia, and
o forth).
enotype–phenotype correlations and clinical implica-
ions of the diagnosis. We have found 3 previously de-
cribed mutations that had been associated with classical
L89P, E358del) or late-onset (A143T) forms of the disease
15–19) and show a quite variable clinical presentation in
ifferent members of our families. This clinical heterogene-
ty could be explained in part in women by the effect of the
andom inactivation of the wild-type or the mutant X
hromosomes in different organs (lyonization) (20,21).
owever, the variability of the clinical presentation is also
emarkable in men. We have also found 1 novel mutation
S238N). The S238N is a missense mutation in exon 5 of
he GLA gene that shows incomplete penetrance in young
arriers (even in men), suggesting that it might be related to
late-onset form of the disease. The S238 amino acid is
lose to the active D231, and the change from Ser to Asn at
38 can adversely affect the folded state of the molecule.
utations in the neighbor W236 and S235 have also been
ssociated with FD (22–24).
One of the most relevant results of our study is that the
iagnosis of FD in 5 index patients has allowed the
dentification of 14 additional carriers. Fabry disease had
ot been previously diagnosed in any of the families. Some
arriers are now receiving enzyme replacement therapy that
ight improve the natural course of their disease. A careful
ollow-up is indicated in all the mutant carriers.
onclusions
ith a screening based on genotyping of patients with low
lasma enzymatic activity, the prevalence of FD in our
opulation with HCM was 1% (0.9% in men and 1.1% in
omen). This diagnosis is relevant because it allows the
dentification of disease carriers that might need enzyme
eplacement therapy.
eprint requests and correspondence: Dr. Lorenzo Monserrat,
ardiology Service, Complejo Hospitalario Universitario Juan
analejo, As Xubias 84, A Coruña 15006, Spain. E-mail: lorenzo_
onserrat@canalejo.org.
EFERENCES
1. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC
clinical expert consensus document on hypertrophic cardiomyopa-
thy: a report of the American College of Cardiology Foundation
Task Force on Clinical Expert Consensus Documents and the
European Society of Cardiology Committee for Practice Guidelines
(Committee to Develop an Expert Consensus Document on Hy-
pertrophic Cardiomyopathy). J Am Coll Cardiol 2003;42:1687–
713.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2403JACC Vol. 50, No. 25, 2007 Monserrat et al.
December 18/25, 2007:2399–403 Fabry Disease in Hypertrophic Cardiomyopathy2. Genomics of Cardiovascular Development, Adaptation, and Remod-
eling. NHLBI Program for Genomic Applications, Harvard Medical
School. Available at: http://www.cardiogenomics.org. Accessed May
2007.
3. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s
disease in men with left ventricular hypertrophy. N Engl J Med
1995;333:288–93.
4. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-
Fabry disease in male patients with late onset hypertrophic cardiomy-
opathy. Circulation 2002;105:1407–11.
5. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry
disease in female patients with late-onset hypertrophic cardiomyopa-
thy. Circulation 2004;110:1047–53.
6. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-
recognized multisystemic disorder: expert recommendations for diag-
nosis, management, and enzyme replacement therapy. Ann Intern
Med 2003;138:338–46.
7. Linhart A, Lubanda C, Palecek T, et al. Cardiac manifestations in
Fabry disease. J Inherit Metab Dis 2001;24 Suppl 2:75–83.
8. Report of the World Health Organization/International Society and
Federation of Cardiology Task Force on the Definition and Classifi-
cation of Cardiomyopathies. Circulation 1996;93:841–2.
9. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M.
Experience from clinical genetics in hypertrophic cardiomyopathy:
proposal for new diagnostic criteria in adult members of affected
families. Heart 1997;77:130–2.
0. Beutler E, Kuhl W. Purification and properties of human alpha-
galactosidases. J Biol Chem 1972;247:7195–200.
1. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay
for lysosomal alpha-galactosidases in human tissues and its application
to Fabry’s disease. Clin Chim Acta 1981;112:247–51.
2. GenBank: U78027.1. Available at: http://www.ncbi.nlm.nih.gov/sites/
gquery?termU78027.1? Accessed October 31, 2007.
3. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for
obstructive hypertrophic cardiomyopathy? Heart 2003;89:929–30.
4. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of
lysosomal storage diseases. JAMA 1999;281:249–54.5. Spada M, Pagliardi S, Yasuda M, et al. High incidence of later-onset
Fabry disease revealed by newborn screening. Am J Hum Genet
2006;79:31–40.
6. Eng CM, Ashley GA, Burgets TS, Enriquez AL, D’Souza M,
Desnick RJ. Fabry disease: thirty-five mutations in the alpha-
galactosidase A gene in patients with classic and variant phenotypes.
Mol Med 1997;3:174–82.
7. Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease:
identification of 50 novel alpha-galactosidase A mutations causing the
classic phenotype and three-dimensional structural analysis of 29
missense mutations. Hum Genomics 2006;2:297–309.
8. Nance CS, Klein CJ, Banikazemi M, et al. Later-onset Fabry disease:
an adult variant presenting with the cramp-fasciculation syndrome.
Arch Neurol 2006;63:453–7.
9. Blanch LC, Meaney C, Morris CP. A sensitive mutation screening
strategy for Fabry disease: detection of nine mutations in the alpha-
galactosidase A gene. Hum Mutat 1996;8:38–43.
0. Dobrovolny R, Dvorakova L, Ledvinova J, et al. Relationship between
X-inactivation and clinical involvement in Fabry heterozygotes. Eleven
novel mutations in the alpha-galactosidase A gene in the Czech and
Slovak population. J Mol Med 2005;83:647–54.
1. Maier EM, Osterrieder S, Whybra C, et al. Disease manifestations
and X inactivation in heterozygous females with Fabry disease. Acta
Paediatr Suppl 2006;95:30–8.
2. Davies JP, Eng CM, Hill JA, et al. Fabry disease: fourteen alpha-
galactosidase A mutations in unrelated families from the United
Kingdom and other European countries. Eur J Hum Genet 1996;4:
219–24.
3. Topaloglu AK, Ashley GA, Tong B, et al. Twenty novel mutations in
the alpha-galactosidase A gene causing Fabry disease. Mol Med
1999;5:806–11.
4. Germain DP, Shabbeer J, Cotigny S, Desnick RJ. Fabry disease:
twenty novel alpha-galactosidase A mutations and genotype-
phenotype correlations in classical and variant phenotypes. Mol Med
2002;8:306–12.
